Shares of other companies:
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
April 14, 2024 Markets Rattle: Iran-Israel Conflict and Economic Data Ahead
Apple’s Technical Climb To $240 By Year-End
April 15, 2024
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading
Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
ABUS Stock News and Mentions of Arbutus Biopharma Corp. Stocktwits
Updated: April 20, 2024 (09:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Arbutus Biopharma Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Arbutus Biopharma Corp. (ABUS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Arbutus Biopharma stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Arbutus Biopharma Corp. (ABUS)
April 18, 2024 (11:30) / "GlobeNewswire" (by Arbutus Biopharma Corporation)
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( cHBV ) infection, today announced ...
In Article Trend: Neutral
April 4, 2024 (18:32) / "Benzinga" (by Vandana Singh)
Arbutus Vs. Moderna Patent Dispute Set for Continuing Discovery - Arbutus Biopharma ( NASDAQ:ABUS ) , Moderna ( NASDAQ:MRNA )
A Delaware District Court sided with Arbutus Biopharma Corporation ABUS and Genevant Sciences in their ongoing patent infringement case against Moderna Inc MRNA COVID-19 vaccine. The companies jointly submitted a claim construction brief to the Delaware district court, seeking clarification on ...
In Article Trend: Neutral
April 4, 2024 (13:34) / "Benzinga" (by Surbhi Jain)
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Is Chart About To Form A Golden Cross? - Moderna ( NASDAQ:MRNA )
Moderna Inc MRNA stock closed lower by 2.32% on Wednesday, as news around Arbutus Biopharma ABUS impacted investor sentiment. Arbutus has received permission to pursue its patent infringement complaint against Moderna. The claim involves the messenger-RNA technology used in Moderna's Covid vaccine.
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:30) / "GlobeNewswire" (by Arbutus Biopharma Corporation)
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., April 04, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( cHBV ) infection, today issued ...
In Article Trend: Neutral
March 20, 2024 (12:15) / "GlobeNewswire" (by Barinthus Biotherapeutics (UK) Limited)
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
OXFORD, United Kingdom, March 20, 2024 ( GLOBE NEWSWIRE ) -- Barinthus Biotherapeutics plc ( NASDAQ: BRNS ) , formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the Company's progress.
In Article Trend: Neutral
March 8, 2024 (12:30) / "GlobeNewswire" (by Arbutus Biopharma Corporation)
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., March 08, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( cHBV ) infection, today announced ...
In Article Trend: Neutral
March 8, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Arbutus to Participate in Two Upcoming Investor Conferences - Arbutus Biopharma ( NASDAQ:ABUS )
WARMINSTER, Pa., March 08, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS, a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( cHBV ) infection, today announced that the ...
In Article Trend: Neutral
February 29, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Arbutus Biopharma ( ABUS ) Reports Q4 Loss, Misses Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 54.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
February 28, 2024 (15:00) / "PR Newswire" (by IntegriChain)
Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board
PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (12:00) / "PR Newswire" (by Nested Therapeutics Inc.)
Nested Therapeutics Strengthens Board of Directors with Appointment of New Chair and Directors
CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced the appointment of three members to its board of directors: John A.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website